Fluticasone furoate and vilanterol trifenatate combination therapy for the treatment of asthma

References

• Fanta C. Drug therapy, asthma. N Engl J Med. 2009;360:1002–1014.
   PubMed Web of Science ®Google Scholar
• Shore S. Airway smooth muscle in asthma - not just more of the same. N Engl J Med. 2004;351:531–532.
   PubMed Web of Science ®Google Scholar
• Johnson P, Roth M, Tamm M, et al. Airway smooth muscle cell proliferation is increased in asthma. Am J Respir Crit Care Med. 2001;164:474–477.
   PubMed Web of Science ®Google Scholar
• Procopiou PA, Barrett VJ, Bevan NJ, et al. Synthesis and structure-activity relationships of long-acting ß2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53(11):4522–4530.
   PubMed Web of Science ®Google Scholar
• Johnson E, Druey K. Heterotrimeric G protein signaling: role in asthma and allergic inflammation. J Allergy Clin Immunol. 2002;109(4):592–602.
   PubMed Web of Science ®Google Scholar
• Barnes P. Biochemical basis of asthma therapy. J Biol Chem. 2011;286(38):32899–32905.
   PubMed Web of Science ®Google Scholar
• Jaeschke R, O’Byrne PM, Mejza F, et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178:1009–1016.
   PubMed Web of Science ®Google Scholar
• Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306(6884):1034–1037.
   PubMed Web of Science ®Google Scholar
• Salpeter S, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144(12):904–912.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss S, Bleecker ER, et al.; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15–26.
   PubMed Web of Science ®Google Scholar
• Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L660–L667.
   PubMed Web of Science ®Google Scholar
• Wadsworth S, Nijmeh H, Hall I. Glucocorticoids increase repair potential in a novel in vitro human airway epithelial wounding model. J Clin Immunol. 2006;26:376–387.
   PubMed Web of Science ®Google Scholar
• West MR, Matthews J, Man Y, et al. Glucocorticoids alter the barrier efficacy of bronchial epithelial cells. Am J Respir Crit Care Med. 2001;163:A997.
   Google Scholar
• Chanez P, Bourdin A, Vachier I, et al. Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1:184–190.
   PubMedGoogle Scholar
• Lundgren R, Söderberg M, Hörstedt P, et al. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J. 1988;1:883–889.
   PubMed Web of Science ®Google Scholar
• Donahue J, Weiss S, Livingston J, et al. Inhaled steroids and the risk of hospitalisation for asthma. JAMA. 1997;277:887–891.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332–336.
   PubMed Web of Science ®Google Scholar
• Friedman H, Navaratnam P, McLaughlin J. Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma. J Asthma. 2010;47(9):994–1000.
   PubMed Web of Science ®Google Scholar
• Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomised open-label study. BMC Pulm Med. 2010;10:1.
   PubMed Web of Science ®Google Scholar
• Baraniuk J, Ali M, Brody D, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med. 1997;155:704–710.
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Lorx R, et al. Ligand-independent activation of the glucocorticoid receptor by beta-2 adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem. 1999;274:1005–1010.
   PubMed Web of Science ®Google Scholar
• Barnes P. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19:182–191.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. National Heart, Lung and Blood Institute (NHLBI); 2015. Available from: www.ginasthma.org
   Google Scholar
• Kankaanranta H, Lahdensuo A, Moilanen E, et al. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res. 2004;5:17.
   PubMed Web of Science ®Google Scholar
• Toogood J, White F, Baskerville J, et al. Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. J Allergy Clin Immunol. 1997;99:186–193.
   PubMed Web of Science ®Google Scholar
• Inman M, Watson R, Rerecich T, et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med. 2001;164:569–574.
   PubMed Web of Science ®Google Scholar
• Silkoff P, McClean P, Spino M, et al. Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest. 2001;119:1322–1328.
   PubMed Web of Science ®Google Scholar
• Gibson P, Powell H, Ducharme F. Differential effects of maintenance long-acting ß-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol. 2007;119:344–350.
   PubMed Web of Science ®Google Scholar
• Price D, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211–216.
   PubMed Web of Science ®Google Scholar
• Smith I, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther. 2003;16:79–95.
   PubMed Web of Science ®Google Scholar
• Newman S. Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther. 2004;4(1):23–22.
   PubMed Web of Science ®Google Scholar
• Thorsson L, Kenyon C, Newman S, et al. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm. 1998;168:119–127.
   Web of Science ®Google Scholar
• Thorsson L, Edsbacker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler P-MDI. Eur Respir J. 1994;7:1839–1844.
   PubMed Web of Science ®Google Scholar
• Borgstrom L, Bondesson E, Moren F, et al. Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur Respir J. 1994;7:69–73.
   PubMed Web of Science ®Google Scholar
• Johnson M. Fluticasone propionate: pharmacokineticand pharmacodynamic implications of different aerosol delivery systems. In: Dalby R, Byron P, Farr S, editors. Respiratory drug delivery. Buffalo Grove (IL): Interpharm Press; 1998. p. 61–70.
   Google Scholar
• Pitcairn G, Reader S, Pavia D, et al. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med. 2005;18(3):264–272.
   PubMedGoogle Scholar
• Oliver A, Bjermer L, Quinn D, et al. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013;68(9):1136–1142.
   PubMed Web of Science ®Google Scholar
• Kempsford RD, Oliver A, Bal J, et al. The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosing. Respir Med. 2013;107(12):1873–1880.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Lotvall J, O’Byrne PM, et al. Fluticasone furoate-vilanterol 100-25µg compared with fluticasone furoate 100µg in asthma: a randomised trial. J Allergy Clin Immunol Pract. 2014;2(5):553–561.
   PubMed Web of Science ®Google Scholar
• Bateman ED, O’Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014;69(4):312–319.
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Bateman ED, Woodcock A, et al. Fluticasone furoate (FF)/vilanterol (100/25mcg or 200/25mcg) or FF (100mcg) in persistent asthma. J Asthma. 2015;52(10):1073–1083.
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;5:CD005535.
   PubMed Web of Science ®Google Scholar
• Ni Chroinin M, Greenstone I, Lasserson TJ, et al. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009;7:CD005307.
   Google Scholar
• O’Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014;43(3):773–782.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Lotvall J, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomised trial. Chest. 2013;144(4):1222–1229.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Allen A, Bareille P, et al. The Pharmacodynamcs, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol. Clin Pharm Drug Dev. 2015;4(1):2–11.
   PubMed Web of Science ®Google Scholar
• Busse WW, O’Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial. Thorax. 2013;68(6):513–520.
   PubMed Web of Science ®Google Scholar
• Allen A, Schenkenberger I, Trivedi R, et al. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013;7(4):397–406.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Allen A, Kelly K, et al. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects. Brit J Clin Pharmacol. 2014;77(3):466–479.
   PubMed Web of Science ®Google Scholar
• Cates CJ, Wieland LS, Olezczuk M, et al. Safety of regular formoterol or salmeterol in adults with asthma: anoverview of Cochrane reviews. Cochrane Database Syst Rev. 2014;2:CD010314.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Drug Safety Communication: drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). Silver Spring (MD): US Department of Health and Human Services; 2010.
   Google Scholar
• Stempel D, Raphiou I, Kral K, et al. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. N Engl J Med. 2016;374: 1822–1830. doi:10.1056/NEJMoa1511049.
   PubMed Web of Science ®Google Scholar
• Allen A, Davis A, Hardes K, et al. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. Clin Ther. 2012;34(12):2316–2332.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Allen A, Bal J, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2013;75(6):1478–1487.
   PubMed Web of Science ®Google Scholar
• Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16(3):408–414.
   PubMed Web of Science ®Google Scholar
• Ward KW, Stelman GJ, Morgan JA, et al. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos. 2004;32(2):172–177.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm. 2009;6(6):1766–1774.
   PubMed Web of Science ®Google Scholar